Savara Inc (NASDAQ:SVRA – Get Rating) Director David A. Ramsay purchased 39,906 shares of the stock in a transaction on Friday, June 17th. The shares were purchased at an average price of $1.33 per share, with a total value of $53,074.98. Following the acquisition, the director now owns 1,541,048 shares in the company, valued at approximately $2,049,593.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of SVRA stock opened at $1.49 on Thursday. The company has a market cap of $169.92 million, a price-to-earnings ratio of -5.73 and a beta of 1.06. Savara Inc has a 52 week low of $1.02 and a 52 week high of $1.82. The company has a quick ratio of 9.47, a current ratio of 9.47 and a debt-to-equity ratio of 0.10. The firm has a 50 day moving average of $1.29 and a 200-day moving average of $1.24.
Savara (NASDAQ:SVRA – Get Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). Analysts anticipate that Savara Inc will post -0.27 earnings per share for the current year.
Savara Company Profile (Get Rating)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
- Get a free copy of the StockNews.com research report on Savara (SVRA)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.